The US Health and Human Services Department is authorized to ‘negotiate’ drug prices in Medicare for the first time in newly-enacted legislation. But the law lacks a clear framework for the process, leaving many key aspects to HHS.
Medicare Price ‘Negotiation’ Process Gets Broad Brush Treatment In New Law
With enactment of the drug pricing reform provisions in the Inflation Reduction Act, stakeholders now turn their attention to the implementing regulations that will be developed by the Centers for Medicare and Medicaid Services.
